Core Insights - Rongchang Biologics (09995) experienced a 5.10% increase in stock price, currently trading at HKD 95.90, with a transaction volume of HKD 287 million [1] Group 1: Clinical Research Announcement - On October 16, Rongchang Biologics announced the results of its Phase III clinical study for Taitasip in treating systemic lupus erythematosus (SLE), published in the prestigious medical journal New England Journal of Medicine (NEJM) [1] - Systemic lupus erythematosus (SLE) is a chronic systemic autoimmune disease that can affect multiple organs and lead to irreversible damage, with over half of patients experiencing organ damage within 2-6 years post-diagnosis [1]

Core Viewpoint - Rongchang Biopharma's Taitasip showed significant efficacy in treating Sjögren's syndrome in the Phase III trial conducted in China, with the 160mg dosage group demonstrating notable statistical differences and clinical improvements compared to the placebo group [1][3]. Group 1: Clinical Data and Efficacy - The Phase III trial results revealed that 71.8% of patients in the Taitasip group experienced an improvement of 3 or more points in the ESSDAI score, significantly higher than the 19.3% in the placebo group, effectively validating its therapeutic efficacy [3]. - Taitasip outperformed competitors like Novartis' Ianalumab and Johnson & Johnson's Nikalimab in improving patient-reported symptoms, indicating a potential for expanding its use beyond systemic lupus erythematosus to another important autoimmune indication [3]. Group 2: Competitive Advantages of Chinese Innovative Drugs - Chinese innovative drugs have established a differentiated, high-cost performance, and global competitive advantage, with core capabilities evolving from drug design to international compliance [4]. - The domestic pharmaceutical industry has transitioned from "me-too" to "me-better" and "first-in-class" drug development, focusing on unique technical breakthroughs rather than just cost competition [4]. - The cost of developing similar targeted drugs in China is approximately one-third of international levels, supported by a large population providing rich clinical resources and the ongoing release of "engineer dividends" in the biopharmaceutical sector [4]. Group 3: Global Clinical Trial Compliance - Leading Chinese pharmaceutical companies have developed the capability to conduct clinical trials according to ICH standards, allowing their clinical data to be directly used for international drug registration, thus lowering barriers for global commercialization [5]. - The Chinese innovative drug sector has progressed from "catching up" to "keeping pace," with some areas even leading, as evidenced by domestic products outperforming international counterparts in head-to-head clinical trials [5]. Group 4: Investment Opportunities in Innovative Drugs - The innovative drug sector is experiencing volatility, primarily due to market style shifts and short-term capital flows, but remains focused on business development (BD) expectations, with the fourth quarter typically accounting for about 40% of annual BD activity [6]. - The Guotai Innovative Drug ETF (517110) tracks the Shanghai-Hong Kong-Shenzhen innovative drug industry index, covering quality innovative drug companies across various segments, reflecting the overall performance of the innovative drug industry [6].

Core Viewpoint - Rongchang Biologics (09995.HK) experienced a significant increase in stock price, rising over 5% to reach 96.45 HKD with a trading volume of 205 million HKD [2] Company Summary - Rongchang Biologics' stock price increased by 5.7% as of the latest report [2] - The current trading price is 96.45 HKD [2] - The total trading volume reached 205 million HKD [2]

Core Viewpoint - Rongchang Biologics (09995) shares rose over 5%, reaching a price of HKD 96.45, following the announcement of positive Phase III clinical trial results for Taitasip in treating systemic lupus erythematosus (SLE) published in the New England Journal of Medicine (NEJM) [1] Group 1: Clinical Trial Results - The Phase III trial achieved its primary endpoint, with 67.1% of patients in the Taitasip group showing significant improvement in disease activity, compared to 32.7% in the placebo group [1] - Taitasip is confirmed as a transformative B-cell therapy targeting BLyS/APRIL dual pathways, highlighting its advantages in treating SLE [1] Group 2: Disease Context and Treatment Landscape - Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that can affect multiple organs and lead to irreversible damage, with over half of patients experiencing organ damage within 2-6 years of diagnosis [1] - Despite existing treatment options such as corticosteroids, antimalarials, immunosuppressants, and biologics, many patients still face challenges with disease activity, indicating a pressing need for new therapies [1] - Taitasip was approved for SLE treatment in China in March 2021 and was included in the national medical insurance drug list by the end of the same year, marking it as the world's first dual-target biologic new drug for SLE [1]

Core Viewpoint - Rongchang Biologics (09995) shares rose over 5%, currently up 5.7% at HKD 96.45, with a trading volume of HKD 205 million, following the announcement of positive Phase III clinical trial results for Taitasip in treating systemic lupus erythematosus (SLE) published in the New England Journal of Medicine (NEJM) [1][1][1] Group 1 - The Phase III trial achieved its primary endpoint, with 67.1% of patients in the Taitasip group showing significant improvement in disease activity compared to 32.7% in the placebo group [1][1][1] - Taitasip, a dual-target biologic therapy for B cells, is highlighted as a transformative treatment for SLE, showcasing its advantages in this therapeutic area [1][1][1] Group 2 - Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that can affect multiple organs and lead to irreversible damage, with over half of patients experiencing organ damage within 2-6 years of diagnosis [1][1][1] - Despite existing treatment options such as corticosteroids, antimalarials, immunosuppressants, and biologics, many patients still face challenges with disease activity, indicating a pressing need for new therapies [1][1][1] - Taitasip was approved for SLE treatment in China in March 2021 and entered the national medical insurance drug list by the end of the same year, marking it as the world's first dual-target biologic new drug for SLE [1][1][1]

Core Viewpoint - Rongchang Bio (09995) has entered into an agreement with SPD Bank Yantai Branch to invest a total of RMB 5 billion in wealth management products, utilizing both idle self-owned funds and idle raised funds [1] Group 1 - The company will invest RMB 400 million of its idle self-owned funds in the wealth management products [1] - The company will also invest RMB 100 million of its idle raised funds in the wealth management products [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並表明概不就因本公告全部或任何部份內容而產生或因依賴該等 內容而引致的任何損失承擔任何責任。 RemeGen Co., Ltd.* 榮 昌 生 物 製 藥（ 煙 台 ）股 份 有 限 公 司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：9995） 須予披露交易 購買理財產品 購買理財產品 本公司第二屆董事會第二十一次會議已於2025年3月27日，(1)審議批准了關 於使用自有資金進行現金管理的決議，根據該決議本公司可使用不超過人民幣 500.0百萬元額度的部分閒置自有資金購買保本型銀行理財產品，以及(2)審議批 准了關於使用閒置募集資金進行現金管理的決議，根據該決議本公司可使用不 超過人民幣140.0百萬元額度的部分閒置募集資金購買保本型銀行理財產品。 董事會宣佈，於2025年10月15日，本公司與浦發銀行煙台分行訂立浦發銀行理 財產品協議，據此本公司同意(1)以人民幣400.0百萬元的閒置自有資金向浦發銀 行煙台分行購買理財產品，以及(2)以人民幣100.0百萬元的閒置募集資金向浦發 銀 ...

Group 1 - Company Rongchang Bio (09995) announced an agreement with Pudong Development Bank Yantai Branch to purchase wealth management products [1] - The company will invest a total of RMB 5 billion, consisting of RMB 4 billion of idle self-owned funds and RMB 1 billion of idle raised funds [1]

Core Viewpoint - Rongchang Biologics (09995.HK) has entered into an agreement with Pudong Development Bank Yantai Branch to invest a total of RMB 5 billion in wealth management products, utilizing both idle self-owned funds and raised funds [1] Group 1 - The company will invest RMB 4 billion of idle self-owned funds in wealth management products [1] - The company will also invest RMB 1 billion of idle raised funds in wealth management products [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並表明概不就因本公告全部或任何部份內容而產生或因依賴該等 內容而引致的任何損失承擔任何責任。 RemeGen Co., Ltd.* 榮 昌 生 物 製 藥（ 煙 台 ）股 份 有 限 公 司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：9995） 須予披露交易 購買理財產品 購買理財產品 本公司第二屆董事會第二十一次會議已於2025年3月27日，(1)審議批准了關 於使用自有資金進行現金管理的決議，根據該決議本公司可使用不超過人民幣 500.0百萬元額度的部分閒置自有資金購買保本型銀行理財產品，以及(2)審議批 准了關於使用閒置募集資金進行現金管理的決議，根據該決議本公司可使用不 超過人民幣140.0百萬元額度的部分閒置募集資金購買保本型銀行理財產品。 董事會宣佈，於2025年10月15日，本公司與浦發銀行煙台分行訂立浦發銀行理 財產品協議，據此本公司同意(1)以人民幣400.0百萬元的閒置自有資金向浦發銀 行煙台分行購買理財產品，以及(2)以人民幣100.0百萬元的閒置募集資金向浦發 銀 ...